Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jul 15:462:123054.
doi: 10.1016/j.jns.2024.123054. Epub 2024 May 31.

Outcomes and differences by occluded vessel after endovascular thrombectomy for isolated medium vessel occlusions

Affiliations
Multicenter Study

Outcomes and differences by occluded vessel after endovascular thrombectomy for isolated medium vessel occlusions

Hidetoshi Matsukawa et al. J Neurol Sci. .

Abstract

Background: The outcomes of endovascular thrombectomy (EVT) for medium vessel occlusions (MeVOs) of specific vascular territories remain unknown. We aimed to investigate EVT outcomes by MeVO locations using the data from an ongoing international multicenter registry.

Methods: Patients with isolated MeVO who underwent EVT between January 2013 and December 2022 were retrospectively analyzed. Isolated MeVO was defined as an occlusion of the A2 or A3 (A2/A3), M2 or M3, and P2 or P3 (P2/P3). Outcomes included a 90-day modified Rankin score (mRS) of 0-2, successful recanalization (modified Thrombolysis in Cerebral Infarction score ≥ 2b), early neurological deterioration (END) or improvement (ENI), and 90-day mortality. END was defined as a worsening of ≥4 points from the baseline National Institutes of Health Stroke Scale (NIHSS) score within 24 h of EVT, while ENI was defined as an improvement of ≥4 points from the baseline NIHSS score within 24 h of EVT.

Results: 1744 MeVOs included. Compared to M2 occlusions (n = 1542, 88.4%), A2/A3 (n = 36, 2.1%) occlusions had lower odds of 90-day mRS 0-2 (adjusted odds ratio [aOR] 0.30, 95% confidence interval [CI] 0.11-0.80), and P2/P3 occlusions (n = 49, 2.8%) had lower odds of successful recanalization (aOR 0.19, 95% CI 0.07-0.50), and higher odds of END (aOR 3.53, 95% CI 1.35-9.25). Other outcomes showed no significant differences.

Conclusions: A2/A3 occlusions were more likely to have worse outcomes compared to M2 occlusions after EVT for patients with isolated MeVOs.

Keywords: Acute ischemic stroke; Anterior cerebral artery; Endovascular thrombectomy; Medium vessel occlusion; Outcomes.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Hidetoshi Matsukawa received a lecture fee from Daiichi-Sankyo and Stryker and consulting services fee from B. Braun. Dr. Kazutaka Uchida received a lecture fee from Daiichi-Sankyo, Bristol-Myers Squibb, Stryker, and Medtronic. Dr. Ali Alawieh: None. Dr. Charles Matouk: Consultant for Stryker, Medtronic, Microvention, Penumbra, and Silk Road Medical. Speaker for Penumbra and Silk Road Medical. Contact PI for NIH Grant R21NS128641. Dr. Mohammad-Mahdi Sowlat: None. Dr. Sameh Samir Elawady: None. Dr. Ilko L Maier: speakers honoraria from Pfizer and Bristol-Myers Squibb. Dr. Pascal Jabbour: None. Dr. Joon-Tae Kim: None. Dr. Stacey Quintero Wolfe: None. Dr. Ansaar Rai: None. Dr. Robert M Starke: RMS research is supported by the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, Department of Health Biomedical Research Grant (21K02AWD-007000) and by National Institute of Health (R01NS111119-01A1) and (UL1TR002736, KL2TR002737) through the Miami Clinical and Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. RMS has an unrestricted research grant from Medtronic and Balt and has consulting and teaching agreements with Penumbra, Abbott, Medtronic, Balt, InNeuroCo, Cerenovus, Naglreiter, Tonbridge, Von Medical, and Optimize Vascular. Dr. Marios-Nikos Psychogios: Grants from the Swiss National Science Foundation (SNF) for the DISTAL trial (33IC30_198783) and TECNO trial (32003B_204977), Grant from Bangerter-Rhyner Stiftung for the DISTAL trial. Unrestricted Grants for the DISTAL trial from Stryker Neurovascular Inc., Phenox GmbH, Penumbra Inc. and Rapid Medical Inc., Sponsor-PI SPINNERS trial (Funded by a Siemens Healthineers AG Grant), Research agreement with Siemens Healthineers AG, Local PI for the ASSIST, EXCELLENT, TENSION, COATING, SURF and ESCAPE-NEXT trials. Speaker fees: Stryker Neurovascular Inc., Medtronic Inc., Penumbra Inc., Acandis GmbH, Phenox GmbH, Siemens Healthineers AG. Dr. Edgar Samaniego: Consultant for Medtronic, Microvention, Cerenovus, and Rapid Medical. Dr. Adam S. Arthur: Consultant for Arsenal, Balt, Johnson and Johnson, Medtronic, Microvention, Penumbra, Perfuze, Scientia, Siemens, Stryker. Research support from Balt, Medtronic, Microvention, Penumbra and Siemens, Shareholder Azimuth, Bendit, Cerebrotech, Endostream, Magneto, Mentice, Neurogami, Neuros, Perfuze, Revbio, Scientia, Serenity, Synchron, Tulavi, Vastrax, VizAI. Dr. Hugo Cuellar: Dr. Hugo Cuellar: Consultant for Medtronic, Penumbra and Microvention. Dr. Brian Howard: None. Dr. Daniele G. Romano: Consultant for Penumbra, Balt, Microvention, Phenox. Dr. Omar Tanweer: Consulting Agreements: Viz.AI, Inc., Penumbra, Inc., Balt, Inc.,Stryker Inc., Imperative Inc. Proctor: Microvention Inc., Medtronic Inc. Educational/Research Grants: Q'apel Inc., Steinberg Foundation. Dr. Justin Mascitelli: None. Dr. Isabel Fragata: None. Dr. Adam Polifka: Consultant for Depuy Synthes and Stryker. Dr. Joshua Osbun: None. Dr. Roberto Crosa: None. Dr. Min S. Park: Consultant for Medtronic. Dr. Waleed Brinjikji: None. Dr. Mark Moss: No conflicts or disclosures. Dr. Travis Dumont: None. Dr. Richard Williamson: Consultant for Medtronic, Stryker, and Synaptive Medical. Dr. Pedro Navia: Consultant for Penumbra, Medtronic, Stryker, Cerenovus and Balt. Dr. Peter Kan: Grants from the NIH (1U18EB029353–01, UG3NS128397) and unrestricted educational grant from Siemens. Consultant for Stryker Neurovascular. Stock ownership in Vena Medical, Deinde, Prometheus, Neurofine, and Vented. Editorial Board for the Journal of Neurointerventional Surgery (JNIS). Dr. Reade De Leacy: Research grants from Siemens Healthineers and Kaneka medical. Consultant for Cerenovus, Stryker Neurovascular and Scientia Vascular. Minor equity interest Vastrax, Borvo medical, Synchron, Endostream, Von Vascular. Dr. Shakeel A Chowdhry: Consultant and proctor for Medtronic and Microvention. Dr. M. Ezzeldin: Speaker for Viz.ai and has stocks in Galaxy Therapeutics. Dr. Alejandro Spiotta: Research support from Penumbra, Stryker, Medtronic and RapidAI. Consultant for Penumbra, Stryker, Terumo, and RapidAI. Dr. Michael R Levitt: Stryker and Medtronic. Equity interest in Synchron, Stroke Diagnostics, Hyperion Surgical, Proprio, Apertur. Financial interest in Fluid Biomed. Consultant for Aeaean Advisers, Metis Innovative and Stereotaxis. Editorial board for Frontiers in Surgery and Journal of NeuroInterventional Surgery (JNIS). Data safety monitoring board for Arsenal Medical. Dr. Shinichi Yoshimura received a lecture fee from Stryker, Medtronic, Johnson & Johnson, Kaneka Medics.

Similar articles

Cited by

References

Publication types

LinkOut - more resources